OBJECTIVES: To evaluate the immunogenicity of sequence-modified HIV env and gag in baboons using DNA prime and protein boost strategy. METHODS: Synthetic sequence-modified HIV gene cassettes were constructed that expressed three different forms of Env proteins, gp140, gp140mut and gp140TM, plus or minus a mutation in the protease-cleavage site. These plasmids were used to immunize baboons (Papio cynocephalus). A group of baboons was also immunized with both env and gag DNA followed by p55Gag virus-like particles (VLP) boost. RESULTS: Modest antibody responses and low or no lymphoproliferative responses were observed following multiple DNA immunizations. In contrast, strong antibodies and substantial antigen-specific lymphoproliferative responses were seen following booster immunizations with oligomeric Env protein (o-gp140US4) in MF59. Neutralizing antibody responses were scored against T cell line adapted HIV-1 strains after the protein boosters, but neutralizing responses were low or absent against homologous and heterologous primary isolate strains. In the group receiving both gag and env vaccines, modest antigen-specific antibody and lymphoproliferative responses were scored after the DNA immunizations; these responses were enhanced several-fold upon boosting with the VLP preparations. The addition of Gag antigen did not interfere with Env-specific antibody responses, but there was a negative effect on the levels of Env-specific lymphoproliferation. CONCLUSIONS: These results highlight the importance of improving the potency of HIV DNA vaccines by enhanced DNA delivery and prime-boost vaccine technologies to generate more robust immune responses in larger animal models. In addition, care must be taken when immunizations with Env and Gag antigens are performed together.
OBJECTIVES: To evaluate the immunogenicity of sequence-modified HIV env and gag in baboons using DNA prime and protein boost strategy. METHODS: Synthetic sequence-modified HIV gene cassettes were constructed that expressed three different forms of Env proteins, gp140, gp140mut and gp140TM, plus or minus a mutation in the protease-cleavage site. These plasmids were used to immunize baboons (Papio cynocephalus). A group of baboons was also immunized with both env and gag DNA followed by p55Gag virus-like particles (VLP) boost. RESULTS: Modest antibody responses and low or no lymphoproliferative responses were observed following multiple DNA immunizations. In contrast, strong antibodies and substantial antigen-specific lymphoproliferative responses were seen following booster immunizations with oligomeric Env protein (o-gp140US4) in MF59. Neutralizing antibody responses were scored against T cell line adapted HIV-1 strains after the protein boosters, but neutralizing responses were low or absent against homologous and heterologous primary isolate strains. In the group receiving both gag and env vaccines, modest antigen-specific antibody and lymphoproliferative responses were scored after the DNA immunizations; these responses were enhanced several-fold upon boosting with the VLP preparations. The addition of Gag antigen did not interfere with Env-specific antibody responses, but there was a negative effect on the levels of Env-specific lymphoproliferation. CONCLUSIONS: These results highlight the importance of improving the potency of HIV DNA vaccines by enhanced DNA delivery and prime-boost vaccine technologies to generate more robust immune responses in larger animal models. In addition, care must be taken when immunizations with Env and Gag antigens are performed together.
Authors: Yuuei Shu; Sarah Winfrey; Zhi-Yong Yang; Ling Xu; Srinivas S Rao; Indresh Srivastava; Susan W Barnett; Gary J Nabel; John R Mascola Journal: Vaccine Date: 2006-11-07 Impact factor: 3.641
Authors: Gerald V Quinnan; Xiao-Fang Yu; Mark G Lewis; Peng Fei Zhang; Gerd Sutter; Peter Silvera; Ming Dong; Anil Choudhary; Phuong T N Sarkis; Peter Bouma; Zhiqiang Zhang; David C Montefiori; Thomas C Vancott; Christopher C Broder Journal: J Virol Date: 2005-03 Impact factor: 5.103
Authors: Kelly R Young; Benjamin E Teal; Yvonne Brooks; Thomas D Green; Joseph F Bower; Ted M Ross Journal: AIDS Res Hum Retroviruses Date: 2004-11 Impact factor: 2.205
Authors: Shixia Wang; James Arthos; John M Lawrence; Donald Van Ryk; Innocent Mboudjeka; Siyuan Shen; Te-Hui W Chou; David C Montefiori; Shan Lu Journal: J Virol Date: 2005-06 Impact factor: 5.103
Authors: Gerald K Chege; Wendy A Burgers; Helen Stutz; Ann E Meyers; Rosamund Chapman; Agano Kiravu; Rubina Bunjun; Enid G Shephard; William R Jacobs; Edward P Rybicki; Anna-Lise Williamson Journal: J Virol Date: 2013-02-28 Impact factor: 5.103
Authors: Shixia Wang; Jeffrey S Kennedy; Kim West; David C Montefiori; Scott Coley; John Lawrence; Siyuan Shen; Sharone Green; Alan L Rothman; Francis A Ennis; James Arthos; Ranajit Pal; Phillip Markham; Shan Lu Journal: Vaccine Date: 2008-07-23 Impact factor: 3.641
Authors: Shixia Wang; Jeffrey S Kennedy; Kim West; David C Montefiori; Scott Coley; John Lawrence; Siyuan Shen; Sharone Green; Alan L Rothman; Francis A Ennis; James Arthos; Ranajit Pal; Phillip Markham; Shan Lu Journal: Vaccine Date: 2008-01-10 Impact factor: 3.641